Potent anti-cancer therapy created using ‘click chemistry’

The study, published in Nature Chemistry, opens up new possibilities for how cutting-edge cancer immunotherapies might be built in future.

The research team created an anti-cancer therapy with three components: one targeting the cancer cell, another recruiting a white blood cell called a T cell to attack the cancer cell, and a third knocking out part of the cancer cell’s defences.

Previously, this type of three-component therapy has only been built using a complex process called protein engineering, in which DNA sequences for multiple proteins are combined and inserted into a single cell.

One of the three-component therapies the researchers built, which used an enzyme called sialidase to strip away sugars that the cancer cell uses to hide itself, was especially effective at killing breast cancer cells in a dish. The researchers said this showed that the enzyme – which only recently started being explored in cancer research – has the potential to be the basis of next-generation anti-cancer agents.

First author Dr Peter Szijj (UCL Chemistry) said: “Click chemistry is a quicker and more adaptable way to build these multifunctional anti-cancer agents than protein engineering. It’s relatively easy to attach click ‘handles’ to proteins so you can try lots of combinations quickly to test what might work best. Using protein engineering, you need a separate mechanism for each component.”

Senior corresponding author Professor Vijay Chudasama (UCL Chemistry) said: “As proteins are large and complex molecules, you require a combination of precise protein modification and reliable click chemistry to attach them together in a controlled manner. We have achieved this and shown our strategy to be an interesting alternative to using the classical protein engineering approach.”

“We hope that by using chemistry to create novel and highly sophisticated multi-protein anti-cancer agents we can inspire chemists to cross the typical boundaries of the discipline to engage in novel applications in areas such as medical imaging, diagnostics and disease therapies.”

Click chemistry relies on two reaction partners (click handles) that can attach to each other very rapidly and selectively, without the production of any toxic by-products. These click handles can be added to proteins, in this case using functionalised pyridazinediones (PDs), allowing the proteins to click neatly together like LEGO.

The pioneers of click chemistry were awarded the 2022 Nobel Prize in Chemistry. Carolyn Bertozzi, the Anne T. and Robert M. Bass professor in the Stanford School of Humanities and Sciences, who is a co-author on this latest paper, was one of three winners of the prize for her work on biorthogonal chemistry – click chemistry in living cells.

Professor Bertozzi said: "This new construct that brings an enzyme building block into the CiTE format has potential as a new modality for cancer immune therapy.” 

For the new paper, researchers at UCL first clicked two antibody fragments together – one fragment binding to a cancer cell, another fragment binding to a T cell so that it would destroy the cancer cell. Similar T cell engagers, created via protein engineering, have already been approved for use in humans and are used to treat cancers such as multiple myeloma, a rare blood cancer, in the United States and Europe.

The team then added a third component, a checkpoint inhibitor, which removes an aspect of a cancer cell’s defences. This component was either a PD-1-blocking antibody fragment, which is already used to treat specific advanced forms of skin or lung cancer and re-awakens immune cells to target cancer cells; or the more experimental sialidase enzyme, which strips away specific sugars (sialic acids) on the surface of the cancer cell as well as on the T cell. These sugars, present on all our cells, are produced in large amounts by cancer cells and help them to hide from our immune system by switching off approaching immune cells.

The research team found that adding either of these components improved the cancer-killing efficiency of the therapy, and that adding sialidase was especially potent.

The researchers also added a fourth molecule, biotin, allowing them to visualise how well the components bound to their respective targets. They said that this could be substituted for another small molecule with a different function – for instance, to minimize side-effects by masking the protein construct until it reaches its intended target: the cancer.

In the paper, the researchers said that using chemistry in this way to create cancer therapies showed “much untapped potential that is still waiting to be uncovered”.

This sialidase enzyme-containing therapeutic now needs to be tested in animals before any trials involving humans could begin.

The research was supported by Wellcome, with further funding from the US’s National Institutes of Health, the Leverhulme Trust, the EU’s Horizon 2020 programme and UKRI.

Links

• The paper in Nature Chemistry
• Professor Vijay Chudasama’s academic profile
• Dr Peter Szijj’s academic profile
• UCL Chemistry
• UCL Mathematical & Physical Sciences
• Professor Carolyn Bertozzi's academic profile
• Stanford School of Humanities and Sciences

Image

• Top: Stock illustration of T cells attacking a cancer cell.
• Middle: A checkpoint inhibitory T cell engager, comprised of (left to right) a sialidase enzyme (purple), an immune cell binding antibody fragment (green) and a cancer cell binding antibody fragment (blue), binding to an immune cell (left) and a cancer cell (right). The sialidase enzyme is removing immunosuppressive sialic acids from the immune cell.

Media contact

Mark Greaves

E: m.greaves [at] ucl.ac.uk